A common genetic signature has been discovered among three cancer prone rare skin diseases

by Carlos III University of MadridGene expression signature in fibroblasts from RDEB, KS and XPC patients, compared to healthy donors (a). An alteration common to the three diseases of 227 genes

Updated on: April 22,2024

A common genetic signature has been discovered among three cancer prone rare skin diseases

by Carlos III University of MadridGene expression signature in fibroblasts from RDEB, KS and XPC patients, compared to healthy donors (a). An alteration common to the three diseases of 227 genes

Updated on:April 22,2024

Inside the institute looking at early cancer

Updated on: July 24,2024

Inside the institute looking at early cancer

Updated on:July 24,2024

2023 cisplatin shortage tied to use of alternatives for head, neck cancer

by Lori SolomonThe 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a study presente

Updated on: October 18,2024

2023 cisplatin shortage tied to use of alternatives for head, neck cancer

by Lori SolomonThe 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a study presente

Updated on:October 18,2024

And improved method for anti-cancer drug detection: How tiny tumor models could transform drug testing

by Songshan Lake Materials LaboratorySchematic of microfluidic chip-based approach for quality assessment and screening of esophageal cancer drugs. A three-dimensional scaffold with inverse opal struc

Updated on: August 03,2024

And improved method for anti-cancer drug detection: How tiny tumor models could transform drug testing

by Songshan Lake Materials LaboratorySchematic of microfluidic chip-based approach for quality assessment and screening of esophageal cancer drugs. A three-dimensional scaffold with inverse opal struc

Updated on:August 03,2024

Opportunistic colonizers: Selectively targeting tumor cells with bacteria

by TranSpreadC@ECN-PL delivers CXB to tumor cells via liposomes anchored to the cell surface and promotes immune cell recruitment to the tumor. The self-lysis circuit ensures that C@ECN-PL does not ac

Updated on: July 08,2024

Opportunistic colonizers: Selectively targeting tumor cells with bacteria

by TranSpreadC@ECN-PL delivers CXB to tumor cells via liposomes anchored to the cell surface and promotes immune cell recruitment to the tumor. The self-lysis circuit ensures that C@ECN-PL does not ac

Updated on:July 08,2024

Female cancer survivors experience accelerated declines in physical function

by Lori SolomonFemale survivors of cancer experience accelerated declines in physical function after diagnosis versus matched controls, according to a study published online Jan. 19 inJAMA Oncol

Updated on: January 02,2024

Female cancer survivors experience accelerated declines in physical function

by Lori SolomonFemale survivors of cancer experience accelerated declines in physical function after diagnosis versus matched controls, according to a study published online Jan. 19 inJAMA Oncol

Updated on:January 02,2024

Research shows novel drug pairing could beat pancreatic cancer

byUniversity of California - San DiegoMouse pancreatic tumors were significantly smaller after being treated with a combination of KRAS inhibitor MRTX1133 and ERBB inhibitor Afatinib (bottom row

Updated on: January 16,2024

Research shows novel drug pairing could beat pancreatic cancer

byUniversity of California - San DiegoMouse pancreatic tumors were significantly smaller after being treated with a combination of KRAS inhibitor MRTX1133 and ERBB inhibitor Afatinib (bottom row

Updated on:January 16,2024

Blood test for brain cancer may be on horizon, research finds

byPennsylvania State UniversityCredit: Pixabay/CC0 Public DomainGlioblastoma (GBM) is the most common and deadliest type of brain cancer with a five-year survival rate of only 5%. Researchers at

Updated on: January 23,2024

Blood test for brain cancer may be on horizon, research finds

byPennsylvania State UniversityCredit: Pixabay/CC0 Public DomainGlioblastoma (GBM) is the most common and deadliest type of brain cancer with a five-year survival rate of only 5%. Researchers at

Updated on:January 23,2024

Enhancing quality of life for brain tumor survivors

by Monique Mita,Griffith UniversityGriffith School of Applied Psychology Professor Tamara Ownsworth said the Tele-Mast program aims to enhance quality of life for brain tumor survivors. Credit:

Updated on: January 07,2024

Enhancing quality of life for brain tumor survivors

by Monique Mita,Griffith UniversityGriffith School of Applied Psychology Professor Tamara Ownsworth said the Tele-Mast program aims to enhance quality of life for brain tumor survivors. Credit:

Updated on:January 07,2024

A new approach to targeting cancer cells

by University of California - RiversideThe Pellecchia lab at UC Riverside is working on an approach in which effective drugs can be obtained by appropriately designing molecules to contain an ary

Updated on: March 27,2024

A new approach to targeting cancer cells

by University of California - RiversideThe Pellecchia lab at UC Riverside is working on an approach in which effective drugs can be obtained by appropriately designing molecules to contain an ary

Updated on:March 27,2024

T cell behavior determines which tumors respond to treatment

by Weill Cornell Medical CollegeCredit: CC0 Public DomainImmunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn't work, and ne

Updated on: May 07,2024

T cell behavior determines which tumors respond to treatment

by Weill Cornell Medical CollegeCredit: CC0 Public DomainImmunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn't work, and ne

Updated on:May 07,2024

Researchers develop CAR T cells that fight prostate cancer in bone

by H. Lee Moffitt Cancer Center & Research InstituteBTN expression and spontaneous gamma/delta T cell infiltration in prostate tumors. (A) Bioinformatic analysis of TCR gamma variable regions

Updated on: February 20,2024

Researchers develop CAR T cells that fight prostate cancer in bone

by H. Lee Moffitt Cancer Center & Research InstituteBTN expression and spontaneous gamma/delta T cell infiltration in prostate tumors. (A) Bioinformatic analysis of TCR gamma variable regions

Updated on:February 20,2024